Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-25

Study Completion Date

2021-12-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

NCT05045482

Hepatic Impairment Cirrhosis Cholestatic Liver Disease

RECRUITING PHASE1

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

NCT04469920

Hepatic Impairment

COMPLETED PHASE1

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

NCT03863574

Non Alcoholic Steatohepatitis

COMPLETED PHASE2

Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

NCT03061721

Non-Alcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis

COMPLETED PHASE2

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

NCT06825559

Cholestatic Liver Disease

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD.

The study will be conducted over a period of up to 33 weeks and will include 5 weeks screening, a 24 week treatment period and 4 week follow-up period. The primary end point of the study is to assess the safety of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD over 24 weeks of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplant; Complications NAFLD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saroglitazar Magnesium 4 mg

Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast

Group Type EXPERIMENTAL

Saroglitazar

Intervention Type DRUG

Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Saroglitazar

Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Not any

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able and willing to give written informed consent.
* Males or females, 18 to 75 years of age.
* Patients who are at least 6 months post-transplant for nonalcoholic steatohepatitis (NASH) or cryptogenic cirrhosis thought to be secondary to NASH are eligible for enrolment.
* The presence of NAFLD determined by Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) prior to enrollment.
* Patients with ≤20% variance in the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin between Visit 1 and Visit 1.1.
* History of medical compliance with immunosuppression.
* Female subjects of non-child bearing potential or on highly effective contraception. For male subjects with female partners of childbearing potential, willing to follow highly effective contraception measures during the study, either by the male participant or his female partner or both.

Exclusion Criteria

* Pregnant or lactating females.
* Patient with abnormal transaminases due to secondary intercurrent illness.
* Patients with bile duct strictures.
* Other causes of chronic liver disease after liver transplantation including autoimmune, viral, and alcoholic liver disease.
* Graft cirrhosis as defined by:

1. Cirrhosis on historical liver biopsy.
2. Evidence of cirrhosis on imaging including portal venous collaterals.
3. Prior history of decompensated liver disease including ascites, hepatic encephalopathy or variceal bleeding.
4. Evidence of esophageal varices on prior endoscopy.
* Body mass index (BMI) \<18 kg/m².
* Subjects with change in body weight \>5% in the 3 months prior to enrollment.
* Subjects requiring corticosteroid or anticoagulation therapy.
* History of myopathies or evidence of active muscle diseases.
* Unstable cardiovascular disease.
* History of bladder disease and/or hematuria or has current hematuria unless due to a urinary tract infection.
* Active malignancy post-liver transplantation.
* History of malignancy in the past 5 years and/or active neoplasm.
* History of chronic rejection of liver transplant graft.
* Acute cellular rejection of liver transplant graft within the past 6 months.
* Evidence of Acute cellular rejection (ACR) or chronic rejection (CR) or alternative etiologies to NAFLD.
* Poorly controlled diabetes as defined by an HbA1c \>8.5% within the past 6 months.
* History of excessive alcohol intake.
* Subject tests positive for a urine drug screen.
* Subject has a history of chronic (uncontrolled) pain.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No